Laetitia Pouzol

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Venues

Neurochemical research

Journal of medicinal chemistry

Clinical and experimental immunology

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

This page only lists publications with an associated author ORCID identifier.

Publications

Laetitia Pouzol, Anna Sassi, Mélanie Tunis, Anaïs Zurbach, Nadège Baumlin, Carmela Gnerre, Daniel S Strasser, Julia Marrie, Enrico Vezzali, Marianne M Martinic
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects. Neurochemical research (2024)
Laetitia Pouzol, Anna Sassi, Mélanie Tunis, Anaïs Zurbach, Nadège Baumlin, Carmela Gnerre, Daniel S Strasser, Julia Marrie, Enrico Vezzali, Marianne M Martinic
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects. Neurochemical research 49 (8) (2024)
Laetitia Pouzol, Anna Sassi, Mélanie Tunis, Anaïs Zurbach, Nadège Baumlin, Carmela Gnerre, Daniel S Strasser, Julia Marrie, Enrico Vezzali, Marianne M Martinic
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects. Neurochemical research 49 (8) (2024)
Laetitia Pouzol, Anna Sassi, Mélanie Tunis, Anaïs Zurbach, Nadège Baumlin, Carmela Gnerre, Daniel S Strasser, Julia Marrie, Enrico Vezzali, Marianne M Martinic
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects. Neurochemical research 49 (8) (2024)
Laetitia Pouzol, Anna Sassi, Mélanie Tunis, Anaïs Zurbach, Nadège Baumlin, Carmela Gnerre, Daniel S Strasser, Julia Marrie, Enrico Vezzali, Marianne M Martinic
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects. Neurochemical research 49 (8) (2024)
Emmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, Eva Hühn, Daniel S Strasser, Markus Rey, Mark J Murphy, Marianne M Martinic, Laetitia Pouzol, Sylvie Froidevaux, Marcel P Keller, Eva Caroff
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. Journal of medicinal chemistry (2023)
Emmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, Eva Hühn, Daniel S Strasser, Markus Rey, Mark J Murphy, Marianne M Martinic, Laetitia Pouzol, Sylvie Froidevaux, Marcel P Keller, Eva Caroff
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. Journal of medicinal chemistry 66 (6) (2023)
Emmanuel A Meyer, Päivi Äänismaa, Eric A Ertel, Eva Hühn, Daniel S Strasser, Markus Rey, Mark J Murphy, Marianne M Martinic, Laetitia Pouzol, Sylvie Froidevaux, Marcel P Keller, Eva Caroff
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. Journal of medicinal chemistry 66 (6) (2023)
Urs Christen, Laetitia Pouzol, Mélanie Tunis, Anna Sassi, Camilla Tondello, Monika Bayer, Edith Hintermann, Daniel S Strasser, Sabrina Schuldes, Ulrich Mentzel, Marianne M Martinic
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes. Clinical and experimental immunology (2023)
Laetitia Pouzol, Nadège Baumlin, Anna Sassi, Mélanie Tunis, Julia Marrie, Enrico Vezzali, Hervé Farine, Ulrich Mentzel, Marianne M Martinic
ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 35 (3) (2021)

Laetitia Pouzol.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Laetitia Pouzol